95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1572739
Quantification of Endogenous and Therapeutic IgG Crossing the Kidney Barrier from Bloodstream to Urine
Provisionally accepted- Memo Therapeutics AG, Schlieren, Switzerland
This study investigates the biodistribution of a therapeutic antibody from serum to urine across the kidney endothelial barrier, contextualizing the findings with existing literature. Our analysis shows the quantitative correlation between serum levels of the intravenously administered antibody rituximab and its urinary concentration, indicating a predictable pharmacokinetic profile. The results align with previous quantitative studies on the biodistribution of endogenous and vaccination induced IgG between serum and urine, confirming that recombinant therapeutic IgG1 passes the kidney endothelial barrier and exhibits similar biodistribution to endogenous IgG. These insights may inform the determination of optimal dosages for therapeutic antibodies targeting the urothelium or renal epithelium.
Keywords: Monoclonal antibody, pharmacokinetic, kidney epithelial barrier, kidney tubular lumen, Urine, Urothelia, therapeutic antibody, Serum
Received: 07 Feb 2025; Accepted: 04 Apr 2025.
Copyright: © 2025 Eicher, Esslinger and Hillenbrand. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Christoph Esslinger, Memo Therapeutics AG, Schlieren, Switzerland
Matthias Hillenbrand, Memo Therapeutics AG, Schlieren, Switzerland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.